<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): March 31, 2009</B>


<P style="font-size: 24pt" align="center"><B>CELGENE CORPORATION<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-16132</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>22-2711928</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>86 Morris Avenue, Summit, New
Jersey<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>07901</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(908) 673-9000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>&nbsp;
<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P>

<P style="font-size: 10pt" align="left"><B>ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION</B>

<P style="font-size: 10pt; margin-left: 5%" align="left">On March&nbsp;31,
2009, Celgene Corporation announced Sol J. Barer, Ph.D., Chairman and Chief
Executive Officer of Celgene will provide an overview of corporate developments
and outlook for 2009 milestones at the 4<SUP>th</SUP> Annual Citi Biotech Day.
During 2009, Celgene expects to advance multiple clinical, regulatory,
commercial and financial initiatives in all areas of its global operations,
underscored by the recent launch of VIDAZA<SUP>&#174;</SUP> in the European
Union and globalization of Celgene sales and operations in more than 70
countries.

<P style="font-size: 10pt; margin-left: 5%" align="left">The information in
this Report, including the exhibit attached hereto, is furnished solely
pursuant to Item 2.02 of this Form 8-K and shall not be deemed
&#8220;filed&#8221; for the purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, or otherwise subject to the liabilities of that section.
Furthermore, the information in this Report, including the exhibit, shall not
be deemed to be incorporated by reference into the filings of the Registrant
under the Securities Act of 1933.

<P style="font-size: 10pt" align="left"><B>ITEM 9.01 FINANCIAL STATEMENTS AND
EXHIBITS.</B>

<P style="font-size: 10pt; margin-left: 5%" align="left">Exhibit&nbsp;99.1
&#8211; Press Release dated March&nbsp;31, 2009

<P style="font-size: 10pt; text-indent: 5%" align="left">This exhibit is
furnished pursuant to Item&nbsp;2.02 and shall not be deemed to be
&#8220;filed.&#8221;

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt" align="left">Pursuant to the requirements of the
Securities and Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="46%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left" colspan="2"><B>CELGENE CORPORATION</B></TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

 <TR valign="bottom">
  <TD valign="top">Date: April&nbsp;1, 2009</TD>
  <TD align="left">By: &nbsp;</TD>
  <TD valign="top" align="left" style="border-bottom: 1px solid #000000">/s/ David W. Gryska</TD>
 </TR>

 <TR valign="top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Name: David W. Gryska<BR>
Title: Senior Vice President and Chief Financial Officer</TD>
 </TR>

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c83375e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 7027}]
{"company-data": {"conformed-name": "CELGENE CORP /DE/", "cik": "0000816284", "assigned-sic": "2834", "irs-number": "222711928", "state-of-incorporation": "DE", "fiscal-year-end": "0501"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-16132", "film-number": "09721341"}, "business-address": {"street1": "86 MORRIS AVENUE", "city": "SUMMIT", "state": "NJ", "zip": "07901", "phone": "(908)673-9000"}, "mail-address": {"street1": "86 MORRIS AVENUE", "city": "SUMMIT", "state": "NJ", "zip": "07901"}}
Form 8-K
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): March 31, 2009
CELGENE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
0-16132
22-2711928
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
86 Morris Avenue, Summit, New
Jersey
07901
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(908) 673-9000
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On March 31,
2009, Celgene Corporation announced Sol J. Barer, Ph.D., Chairman and Chief
Executive Officer of Celgene will provide an overview of corporate developments
and outlook for 2009 milestones at the 4
th
Annual Citi Biotech Day.
During 2009, Celgene expects to advance multiple clinical, regulatory,
commercial and financial initiatives in all areas of its global operations,
underscored by the recent launch of VIDAZA
®
in the European
Union and globalization of Celgene sales and operations in more than 70
countries.
The information in
this Report, including the exhibit attached hereto, is furnished solely
pursuant to Item 2.02 of this Form 8-K and shall not be deemed
"filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, or otherwise subject to the liabilities of that section.
Furthermore, the information in this Report, including the exhibit, shall not
be deemed to be incorporated by reference into the filings of the Registrant
under the Securities Act of 1933.
ITEM 9.01 FINANCIAL STATEMENTS AND
EXHIBITS.
Exhibit 99.1
– Press Release dated March 31, 2009
This exhibit is
furnished pursuant to Item 2.02 and shall not be deemed to be
"filed."
SIGNATURES
Pursuant to the requirements of the
Securities and Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
CELGENE CORPORATION
Date: April 1, 2009
By:
/s/ David W. Gryska
Name: David W. Gryska
Title: Senior Vice President and Chief Financial Officer